Prolonging Ticagrelor Beyond a Year of Acute Coronary Syndrome: Worth or Harmful?

Title:Prolonging Ticagrelor Beyond a Year of Acute Coronary Syndrome: Worth or Harmful?

Volume: 16 Issue: 5

Author(s): Daniel Aradi*, Dome Dezsi, Gabor Veress and Bela Merkely

Affiliation:

• Heart Center Balatonfured, Balatonfured,Hungary

Keywords: Bleeding, clopidogrel, late outcomes, PCI, prasugrel, thrombosis, ticagrelor.

Abstract: Platelet activation plays a central role in triggering and complicating acute coronary syndromes, especially in case of stent thrombosis and myocardial infarction. On top of aspirin, P2Y12- inhibitors are successfully used to treat and prevent these events for a duration of one year after an acute coronary episode or 6 months after drug-eluting stent implantation. However, patients with acute coronary syndromes remain at heightened risk for recurrent ischemic events after the recommended durations of P2Y12-inhibitors and therefore, prolonging treatment is often considered in clinical practice. However, the higher risk for bleeding limits the utility of such approach to a restricted group who is still poorly defined by available measures. This review aims to discuss potential benefits and highlight important pitfalls of prolonged treatment with P2Y12-inhibitors, with a focus on ticagrelor, an attractive reversible P2Y12-inhibitor in patients after myocardial infarction.

Cite this article as:

Aradi Daniel*, Dezsi Dome, Veress Gabor and Merkely Bela, Prolonging Ticagrelor Beyond a Year of Acute Coronary Syndrome: Worth or Harmful?, Current Vascular Pharmacology 2018; 16 (5) . https://dx.doi.org/10.2174/1570161116666180117104613